Core Laboratories (CLB) Tops Q2 EPS by 5c, Offers Q3 & Q4 Guidance

Core Laboratories (NYSE: CLB) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $204 million versus the consensus estimate of $194.39 million.

Core Laboratories sees Q3 2015 EPS of $0.82-$0.84, versus the consensus of $0.80. Core Laboratories sees Q3 2015 revenue of $203-205 million, versus the consensus of $195 million.

Core Laboratories sees Q4 2015 EPS of $0.84-$0.86, versus the consensus of $0.85. Core Laboratories sees Q4 2015 revenue of $205-210 million, versus the consensus of $200 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
• Voyager Technologies, Inc. (VOYG) Misses Q3 EPS by 55c; Offer Guidance
• aTyr Pharma (LIFE) Reports Q3 EPS of $0.53; Offers Guidance